ClinicalTrials.gg
CompletedNCT01831089Updated Apr 10, 2020Results posted

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

A Phase 1 interventional study of PM01183 + paclitaxel +/- bevacizumab in Breast Cancer, Ovarian Cancer and Gynecological Cancer, sponsored by PharmaMar. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-10.

Sponsored by PharmaMar · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Enrollment
159th of 361
69 · median 60
Started
2013
with 20 others
Phase 1
38 of 373
3 open now
Registered
233rd of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 159th largest by enrollment of the 361 interventional ones that give a count, is one of 21 that started in 2013, is one of 38 in phase 1, and was the 233rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors

Read the detailed description

Clinical trial to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with weekly paclitaxel, with or without bevacizumab. Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a selected cohort of patients to characterize the safety profile and feasibility of this combination, to obtain preliminary information on antitumor activity, to obtain preliminary information on quality of life (QoL), to characterize the pharmacokinetics (PK) of this combination and to detect major drug-drug PK interactions and PK(pharmacokinetic)/PD(pharmacodynamic) correlation and to conduct an exploratory pharmacogenomic(PGx) analysis in patients with selected advanced solid tumors.

03

Conditions studied

  • Breast Cancer
  • Ovarian Cancer
  • Gynecological Cancer
  • Head and Neck Carcinoma
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Non-squamous Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily signed and dated written
  • Age between 18 and 75 years old (both inclusive)
  • (ECOG) performance status (PS) of ≤ 1
  • ≥ 3 months.
  • Patients with a histologically/ confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:

    1. Breast cancer
    2. Epithelial ovarian cancer or gynecological cancer
    3. Head and neck squamous cell carcinoma
    4. Non-small cell lung cancer
    5. Small cell lung cancer
    6. Platinum- germ-cell tumors.
    7. Adenocarcinoma or carcinoma of unknown primary site
  • Adequate bone marrow, renal, hepatic, and metabolic function
  • Recovery to grade ≤ 1 or to baseline from any Adverse Event (AE) derived from previous treatment (excluding alopecia of any grade).
  • Pre-menopausal women must have a negative pregnancy test before study entry and agree to use a medically acceptable method of throughout the treatment period and for at least six weeks after treatment discontinuation

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxel
  • Patients who have previously discontinued paclitaxel-based regimes due to drug related toxicity.
  • Known to bevacizumab or any component of its formulation
  • Patients who have previously discontinued bevacizumab-containing regimes due to drug-related toxicity.
  • More than three
  • Less than three months since last taxane-containing therapy.
  • :

    1. Less than three weeks since the last chemotherapy-containing regimen
    2. Less than three weeks since the last radiotherapy dose
    3. Less than four weeks since last monoclonal antibody-containing therapy
  • Concomitant diseases/conditions:

Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary embolism within last year, arrhythmia, hepatopathy, uncontrolled infection, hemoptysis or oxygen requiring dyspnea, known infection, bleeding risk, muscular problems, peripheral neuropathy, Symptomatic or progressive or .

  • Men or pre-menopausal women who are not using an effective method of as previously described; actively breast feeding women.
  • Patients who have pelvic irradiation with doses ≥ 45 Grays (Gy).
  • History of previous bone marrow and/or stem cell transplantation.
  • Confirmed bone marrow involvement
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Treatment

    PM01183 + paclitaxel +/- bevacizumab

    Drug: PM01183 + paclitaxel +/- bevacizumab

Interventions

  • DrugPM01183 + paclitaxel +/- bevacizumab

    Drug pages: PM 01183 · Paclitaxel · Bevacizumab

    PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion paclitaxel: 6 mg/ml concentrate for solution for infusion bevacizumab: 25 mg/ml concentrate for solution for infusion Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    The MTD will be the lowest level at which one third or more evaluable patients experience a DLT in Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.

    Time frame: The MTD was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)

  2. Recommended Dose (RD)

    The RD will be the highest DL explored with less than one third of the patients experiencing a DLT during Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.

    Time frame: The RD was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)

  3. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

    DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.

    Time frame: DLT was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)

Secondary outcomes

  1. Best Tumor Response

    Best overall response:Best response recorded from the start of the study treatment until the end of treatment Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm Partial Response (PR):At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression) Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF):symptomatic deterioration or death due to progression

    Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)

  2. Progression-free Survival

    Progression-free survival (PFS) was defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death had not occurred at the time of the analysis, the PFS was censored.

    Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)

  3. Duration of Response (DR)

    Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented

    Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)

  4. Quality of Life (QoL)

    Change from baseline to last cycle. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL scale scores. The EORTC QLQ-C15-PAL is an abbreviated 15-item version of the EORTC QLQ-C30 (version 3.0) developed for palliative care. Wilcoxon signed ranks test repeat-measure analyses of variance were used to measure the change value from baseline value. Data has to be analysed following the corresponding EORTC manual http://www.eortc.be/qol/files/SCManualQLQ-C15-PAL.pdf and the overall quality of life assessment is contained in 0 to 100 where a higher value represents a better state.

    Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)

07

Results

Posted Mar 20, 2020

Participant flow

A total of 69 patients were enrolled at 3 investigational sites: 55 Group A (paclitaxel plus PM01183) and 14 Group B (paclitaxel+PM01183 and BEV). Patients participated in this trial between 15/Oct/2013 and 14/Jul/2016 (last FU). The first dose of the first cycle was given on 23/Oct/2013 and the last dose of the last cycle was given on 23/Jun/2016

Cohort I: Dose Level 1
Participant flow — Cohort I: Dose Level 1
MilestonePaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Started300000
Completed000000
Not completed300000
Withdrew: Progressive disease300000
Cohort II: Dose Level 2
Participant flow — Cohort II: Dose Level 2
MilestonePaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Started030000
Completed000000
Not completed030000
Withdrew: Progressive disease020000
Withdrew: Clinical progressive disease010000
Cohort III: Dose Level 3
Participant flow — Cohort III: Dose Level 3
MilestonePaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Started006000
Completed000000
Not completed006000
Withdrew: Progressive disease003000
Withdrew: Withdrawal by subject001000
Withdrew: Adverse event001000
Withdrew: Global end of study001000
Cohort IV: Dose Level 4
Participant flow — Cohort IV: Dose Level 4
MilestonePaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Started000600
Completed000000
Not completed000600
Withdrew: Progressive disease000600
Cohort V: Dose Level 5
Participant flow — Cohort V: Dose Level 5
MilestonePaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Started0000370
Completed000000
Not completed0000370
Withdrew: Progressive disease0000300
Withdrew: Withdrawal by subject000030
Withdrew: Death000010
Withdrew: Global end of study000020
Withdrew: Lost to follow-up000010
Cohort B: Arm B
Participant flow — Cohort B: Arm B
MilestonePaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Started0000014
Completed000000
Not completed0000014
Withdrew: Progressive disease000008
Withdrew: Physician decision000002
Withdrew: Never treated000002
Withdrew: Adverse event000001
Withdrew: Global end of study000001

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

The MTD will be the lowest level at which one third or more evaluable patients experience a DLT in Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.

Time frame:
The MTD was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)
Reported as:
Number · mg/m2 / mg FD
Maximum Tolerated Dose (MTD)
mg/m2 / mg FDGroup A (Paclitaxel/PM01183)
Maximum Tolerated Dose (MTD)NA
PrimaryRecommended Dose (RD)

The RD will be the highest DL explored with less than one third of the patients experiencing a DLT during Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.

Time frame:
The RD was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)
Reported as:
Number · mg/m2 / mg FD
Recommended Dose (RD)
mg/m2 / mg FDGroup A (Paclitaxel/PM01183)
Recommended Dose (RD)NA
PrimaryNumber of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.

Time frame:
DLT was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
ParticipantsPaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)002363
SecondaryBest Tumor Response

Best overall response:Best response recorded from the start of the study treatment until the end of treatment Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm Partial Response (PR):At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression) Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF):symptomatic deterioration or death due to progression

Time frame:
Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
Reported as:
Count of participants · Participants
Best Tumor Response
ParticipantsPaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
CR000011
PR1024124
SD ≥3 months121164
SD <3 months001010
PD1121120
Early PD000010
TF000001
SecondaryProgression-free Survival

Progression-free survival (PFS) was defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death had not occurred at the time of the analysis, the PFS was censored.

Time frame:
Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
Reported as:
Median · months
Progression-free Survival
monthsPaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Progression-free Survival3.5 (1.7 to 5.6)3.1 (1.9 to 7.4)3.1 (1.0 to NA)5.4 (1.7 to 8.8)3.9 (1.9 to 6.0)6.7 (2.4 to 9.3)
SecondaryDuration of Response (DR)

Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented

Time frame:
Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
Reported as:
Median · months
Duration of Response (DR)
monthsPaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Duration of Response (DR)1.6 (NA to NA)—NA (2.0 to NA)2.2 (0.9 to 4.7)4.1 (2.1 to 8.3)4.6 (1.4 to NA)
SecondaryQuality of Life (QoL)

Change from baseline to last cycle. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL scale scores. The EORTC QLQ-C15-PAL is an abbreviated 15-item version of the EORTC QLQ-C30 (version 3.0) developed for palliative care. Wilcoxon signed ranks test repeat-measure analyses of variance were used to measure the change value from baseline value. Data has to be analysed following the corresponding EORTC manual http://www.eortc.be/qol/files/SCManualQLQ-C15-PAL.pdf and the overall quality of life assessment is contained in 0 to 100 where a higher value represents a better state.

Time frame:
Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
Reported as:
Mean · score on a scale
Quality of Life (QoL)
score on a scalePaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Pain5.6 ± 9.68.3 ± 11.8-13.3 ± 21.713.3 ± 13.9-4.2 ± 21.012.5 ± 30.5
Dyspnea0.0 ± 0.00.0 ± 47.1-6.7 ± 27.96.7 ± 14.911.1 ± 25.412.5 ± 24.8
Insomnia0.0 ± 33.316.7 ± 23.60.0 ± 0.0-6.7 ± 14.94.2 ± 34.5-12.5 ± 30.5
Appetite loss-22.2 ± 38.50.0 ± 0.0-6.7 ± 14.90.0 ± 0.01.4 ± 30.316.7 ± 25.2
Constipation11.1 ± 19.20.0 ± 0.06.7 ± 14.913.3 ± 29.8-2.8 ± 23.98.3 ± 23.6
Overall QoL5.6 ± 9.6-16.7 ± 0.0-8.3 ± 21.5-6.7 ± 19.0-6.3 ± 22.4-10.4 ± 17.7
Physical functioning-11.1 ± 19.2-6.7 ± 9.4-2.7 ± 6.0-13.3 ± 8.2-2.8 ± 19.8-8.3 ± 17.0
Fatigue3.7 ± 33.90.0 ± 0.0-2.2 ± 24.111.1 ± 13.66.5 ± 23.42.8 ± 22.0
Nausea / vomiting-5.6 ± 9.68.3 ± 11.80.0 ± 11.83.3 ± 7.53.5 ± 9.82.4 ± 6.3
Emotional functioning16.7 ± 28.9-8.3 ± 35.40.0 ± 11.85.0 ± 33.16.3 ± 18.45.2 ± 16.0

Adverse events

Collected over Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]0/3 (0%)0/3 (0%)3/3 (100%)
Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]0/3 (0%)0/3 (0%)3/3 (100%)
Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD0/6 (0%)3/6 (50%)6/6 (100%)
Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]0/6 (0%)2/6 (33.3%)6/6 (100%)
Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]3/37 (8.1%)15/37 (40.5%)36/37 (97.3%)
Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg2/14 (14.3%)7/14 (50%)12/14 (85.7%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventPaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
Febrile neutropeniaBlood and lymphatic system disorders0/30/32/61/61/372/14
Intestinal obstructionGastrointestinal disorders0/30/32/60/60/371/14
PyrexiaGeneral disorders0/30/30/61/61/370/14
NeutropeniaBlood and lymphatic system disorders0/30/31/60/61/370/14
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/30/30/60/60/372/14
Chest painGeneral disorders0/30/30/60/60/371/14
Large intestine perforationGastrointestinal disorders0/30/30/60/60/371/14
Gallbladder obstructionHepatobiliary disorders0/30/30/60/60/371/14
Back painMusculoskeletal and connective tissue disorders0/30/30/60/60/371/14
Abdominal abscessInfections and infestations0/30/30/60/60/371/14
Most frequent other events
Showing 10 of 136
Most frequent other events
EventPaclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg
FatigueGeneral disorders2/33/36/66/627/3710/14
NeutropeniaBlood and lymphatic system disorders0/31/34/65/610/373/14
AlopeciaSkin and subcutaneous tissue disorders1/31/31/65/69/375/14
PyrexiaGeneral disorders0/32/31/62/67/370/14
CoughRespiratory, thoracic and mediastinal disorders1/31/34/62/611/373/14
DiarrhoeaGastrointestinal disorders2/32/32/62/613/375/14
NauseaGastrointestinal disorders2/32/32/64/624/376/14
VomitingGastrointestinal disorders1/31/32/63/619/373/14
Oedema peripheralGeneral disorders0/30/30/63/64/371/14
AnaemiaBlood and lymphatic system disorders1/30/33/61/67/373/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kgTotal
<=18 years0000000
Between 18 and 65 years2365231251
>=65 years100114218
Age, Continuous
Age, Continuous(years)Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kgTotal
Median57 (53 to 72)50 (31 to 55)53.5 (41 to 63)46.5 (38 to 68)61.0 (38 to 74)57 (47 to 72)57 (31 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kgTotal
Female234526848
Male102111621
Region of Enrollment
Region of Enrollment(Participants)Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD]Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FDPaclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD]Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kgTotal
Switzerland12116112
Spain213412628
United States002119729
08

Study locations

3 sites
  • New York, New York, United States
  • Madrid, Spain
  • Bellinzona, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2020, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2013
First posted
Apr 15, 2013
Start
Sep 2013
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Mar 20, 2020
Last update
Apr 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01831089
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Apr 15, 2013
Start date
Sep 2013
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Mar 20, 2020
Last update
Apr 10, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PM 01183 · Paclitaxel · Bevacizumab

Start the discussion